Biotecnol is an immune-oncology company focusing on the development of multifunctional antibodies for highly heterogeneous oncological situations. Biotecnol is developing oncological treatments for rare diseases such as triple-negative breast cancer, malignant mesothelioma, and other highly-aggressive and mutated cancer subtypes.

Biotecnol is a private biopharmaceutical company working in the field of immuno-oncology. Biotecnol develops highly-specific antibody-based immunotherapies which activates and directs the defences of a patient’s own immune system, such as their own Killer T-Cells (T-lymphocytes that kill cancer cells) to fight various types of cancers where standard of care treatments have shown little or no benefit.